Core Viewpoint - The company, Rendu Biotech, reported a decline in revenue and net profit for the first half of 2025, but is focusing on technological innovation and international expansion to drive long-term growth [2][3][4]. Financial Performance - The company achieved operating revenue of 81.24 million yuan, a year-on-year decrease of 6.27% [2]. - The net profit attributable to shareholders was 2.038 million yuan, down 52.94% year-on-year [2]. - Despite challenges, the company saw over 50% year-on-year growth in sales of certain blood test products, particularly in the hepatitis B sector [2]. R&D and Innovation - The company has developed a new technology platform called "Digital SAT + Automatic Supporting Equipment DigiNAT," which offers significant advantages over traditional digital PCR technology [3]. - The company is focusing on RNA digital precision quantitative detection products, particularly in cancer screening and diagnosis, with ongoing development of prostate and bladder cancer tests [3]. - The global liquid biopsy market is expected to grow at a compound annual growth rate of over 20% in the next five years, with urine testing being one of the fastest-growing segments [3]. International Expansion - The company has made strides in international markets, signing contracts with users in the US, Japan, Indonesia, and Vietnam, and achieving its first sale in India [4]. - The company’s chlamydia (CT) and human papillomavirus (HPV) test kits received IVDR CE certification from a European Union notified body, allowing entry into the EU market [4]. - The certification highlights the company's strengths in product development and regulatory compliance, positioning it well for future international registrations [4].

格隆汇8月29日丨仁度生物(688193.SH)发布中报，2025上半年实现营业总收入8124.25万元，同比下降 6.27%；归属母公司股东净利润203.8万元，同比下降52.94%；基本每股收益为0.06元。 ...

Core Viewpoint - Shanghai Rendu Biotech Co., Ltd. has obtained IVDR CE certification for three nucleic acid testing products, enabling entry into the EU market and enhancing competitiveness in the in vitro diagnostic product sector [12]. Group 1: Company Overview - The company is identified as Shanghai Rendu Biotech Co., Ltd. with stock code 688193 [12]. - The company held its second supervisory board meeting on August 28, 2025, with full attendance [7]. Group 2: Financial Data - The company raised a total of RMB 726.5 million through its initial public offering, with a net amount of RMB 652.76 million after deducting issuance costs [24][25]. - As of the end of the reporting period, the company had utilized RMB 283.99 million of the raised funds, with RMB 31.16 million used in the first half of 2025 [26]. Group 3: Significant Events - The company plans to participate in a collective performance briefing for the medical device industry on September 17, 2025, to discuss its 2025 semi-annual results [16][18]. - The supervisory board approved the semi-annual report and the special report on the use of raised funds, confirming compliance with relevant regulations [10][44]. Group 4: Regulatory Compliance - The company has established a management system for the storage and use of raised funds, ensuring compliance with regulatory requirements [26]. - The company has not engaged in any violations regarding the use of raised funds, maintaining transparency and adherence to regulations [38].

Core Viewpoint - The report highlights the financial performance and operational developments of Shanghai Rendu Biotechnology Co., Ltd. for the first half of 2025, indicating a decrease in revenue and profit due to various market factors while emphasizing the company's focus on RNA molecular diagnostics and innovation in technology platforms [1][3][12]. Company Overview - Shanghai Rendu Biotechnology Co., Ltd. is a leading enterprise in the field of RNA isothermal amplification technology and products, focusing on molecular diagnostics [3][6]. - The company operates in the medical device manufacturing industry, specifically in the production of in vitro diagnostic products [5][6]. Financial Performance - The company reported a revenue of approximately 81.24 million yuan for the first half of 2025, a decrease of 6.27% compared to the same period last year [3]. - The total profit for the period was approximately 764,383 yuan, reflecting a significant decline of 79.97% year-on-year [3]. - The net profit attributable to shareholders was approximately 2.04 million yuan, down 52.94% from the previous year [3]. Business Segments - The main business segments include molecular diagnostic reagents, instrument equipment, and third-party testing services [4][6]. - The company has developed a range of diagnostic products for reproductive, respiratory, digestive, and blood-borne diseases, with nearly 20 products recognized by major hospitals and laboratories [4][6]. Technological Innovation - The company has a patented technology platform for RNA real-time fluorescence isothermal amplification (SAT), which is crucial for its diagnostic products [2][16]. - A new technology platform, "Digital SAT + DigiNAT," has been developed, offering significant advantages over traditional methods, including simplified sample processing and faster detection [12][18]. Market Position - The company has established a strong market presence in the field of RNA molecular diagnostics, particularly in the detection of infectious diseases, with a focus on blood-borne pathogens [7][9]. - The RNA molecular diagnostics market in China is rapidly growing, with the company positioned to capitalize on this trend due to its innovative products and technologies [7][8]. Regulatory Compliance - The company has successfully obtained medical device registration for several new products, enhancing its product portfolio in the blood-borne pathogen detection field [13][20]. - The company adheres to national standards and regulations, ensuring compliance in its operations and product offerings [11][12]. Strategic Focus - The company is committed to continuous innovation and market expansion, with a focus on developing new products and enhancing its technological capabilities [12][14]. - Efforts are being made to strengthen partnerships with key clients and expand into international markets, including recent agreements with clients in the United States, Japan, and other countries [14][18].

Company Overview - Shanghai Rendu Biotechnology Co., Ltd. is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board with the stock code 688193 [2] - The company reported total assets of approximately 984.94 million yuan at the end of the reporting period, a decrease of 0.95% compared to the previous year [2] - The net assets attributable to shareholders of the listed company were not specified in the provided data [2] Financial Performance - The company's operating revenue for the reporting period was approximately 81.24 million yuan, reflecting a decline of 6.27% compared to the same period last year [2] - The total profit for the period was approximately 764.38 thousand yuan, a significant decrease of 79.97% year-on-year [2] - The net profit attributable to shareholders of the listed company was reported as -4.28 million yuan, indicating a substantial loss compared to a profit of -143.37 thousand yuan in the previous year [2] - The net cash flow from operating activities was -1.04 million yuan, a decrease of 109.96% compared to the previous year [2] Shareholder Information - As of the reporting period, the total number of shareholders was 3,495 [3] - The largest shareholder, residing overseas, holds 19.65% of the shares, amounting to 7.86 million shares [3] - The second-largest shareholder, also overseas, holds 15.44% of the shares, totaling 6.18 million shares [3] Important Events - The report indicates that there were no significant changes in the company's operating conditions during the reporting period [5]

Core Viewpoint - The company has actively implemented its "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on R&D and innovation to enhance core competitiveness and investor returns [1][2][3]. Group 1: R&D and Innovation - The company is one of the earliest domestic enterprises specializing in RNA isothermal amplification technology, aiming to develop innovative diagnostic technologies and products to meet unmet clinical needs [1]. - The company has successfully developed a new technology platform "Digital SAT + Fully Automatic Supporting Equipment DigiNAT," which shows significant advantages over digital PCR technology, including simplified sample processing and faster detection speed [2][3]. - The company has initiated the development of RNA digital quantitative detection products, focusing on tumor screening and diagnosis, with progress in products for prostate cancer and bladder cancer [3]. Group 2: Market Development and Marketing Capability - The company has expanded its marketing network, developing 91 new terminal customers and adding 206 new products to hospitals, resulting in over 50% year-on-year revenue growth for certain blood-related products [4][5]. - The company has strengthened its academic promotion system, enhancing brand recognition and professional influence in core product lines [5]. Group 3: Internal Control and Cost Management - The company emphasizes cost control and efficiency enhancement, optimizing procurement management and improving resource utilization to lower operational costs [6]. - The company is actively monitoring industry policies and regulations to enhance internal control systems and ensure effective execution [6]. Group 4: Corporate Governance - The company is committed to improving its corporate governance structure and compliance awareness among key stakeholders, including major shareholders and executives [6][7]. - The company organizes training for its board members to enhance their understanding of securities market regulations and compliance [7]. Group 5: Investor Relations and Shareholder Returns - The company prioritizes investor relations management, ensuring accurate and timely information disclosure to maintain a positive market image [7]. - The company has established a reasonable profit distribution plan to reward investors, having completed the distribution of cash dividends for 2024 [7].

Fundraising Overview - The company raised a total of RMB 726.5 million by issuing 10 million shares at RMB 72.65 each, with a net amount of RMB 652.76 million after deducting issuance costs of RMB 73.74 million [1][2] - As of the report date, all raised funds have been received and verified by an accounting firm [2] Fund Utilization and Balance - Cumulative usage of the raised funds reached RMB 283.99 million, with RMB 31.16 million used in the first half of 2025 [2][6] - The company has RMB 380 million temporarily idle for cash management, with a remaining balance of RMB 18.24 million in the fundraising account [2][6] Fund Management System - The company established a fundraising management system to ensure the safety and efficiency of fund usage, complying with relevant laws and regulations [2][3] - A tripartite supervision agreement was signed with a bank and a sponsor to ensure strict approval for fund usage [3] Cash Management of Idle Funds - The company approved the use of up to RMB 430 million of temporarily idle funds for cash management, investing in safe and liquid financial products [4][5] - The report details various structured deposits and their expected returns, indicating a focus on capital preservation [5][6] Compliance and Reporting - The company has adhered to disclosure requirements, ensuring timely and accurate reporting of fundraising and usage status, with no violations noted [6][7]

上海仁度生物科技股份有限公司 关于参加 2025 年半年度科创板医疗器械及医疗设备 行业集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 09 月 17 日（星期三）15:00-17:00 会议召开地点：上海证券交易所上证路演中心（https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2025 年 9 月 10 日（星期三）至 9 月 16 日（星期二）16:00 前 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@rdbio.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 证券代码：688193 证券简称：仁度生物 公告编号：2025-039 上海仁度生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 ...

一、获证产品的基本信息 注：上述 CE 认证基于欧盟医疗器械法规（REGULATION (EU) 2017/746，简称 IVDR） 二、对公司的影响 新的欧盟体外诊断医疗器械法规（IVDR，EU2017/746）系替代原欧盟体外 诊断医疗器械指令（IVDD，98/79/EC）对欧盟市场的体外诊断医疗器械进行管 理。 本次 IVDR CE 证书的获得，标志着公司相关产品已经具备进入欧盟市场的 必要条件，有利于进一步提升公司体外诊断产品在欧盟市场的综合竞争力，将对 公司未来经营产生积极影响。 证券代码：688193 证券简称：仁度生物 公告编号：2025-038 上海仁度生物科技股份有限公司 关于公司产品获得 IVDR CE 认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，上海仁度生物科技股份有限公司（以下简称"公司"）3 项核酸检测 试剂产品获得了由欧盟公告机构 TÜV 南德意志集团签发的 IVDR CE 证书。具体 获证情况如下： | 序号 | 产品名称 | 分类 | 注册证有效 期 | 证书编号 | ...

证券代码：688193 证券简称：仁度生物 公告编号：2025-035 上海仁度生物科技股份有限公司 2025 年半年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司募集资金监管规则》、《上海证券 交易所科创板上市公司自律监管指引第 1 号——规范运作》以及《上海证券交易 所上市公司自律监管指南第 1 号——公告格式》的相关规定，上海仁度生物科技 股份有限公司（以下简称"公司"、"本公司"）就 2025 年半年度（或"报告 期"）募集资金存放与使用情况作如下专项报告： 一、募集资金基本情况 经中国证券监督管理委员会作出《关于同意上海仁度生物科技股份有限公司 首次公开发行股票注册的批复》（证监许可[2022]332 号文），并经上海证券交 易所同意，公司于 2022 年 3 月向社会公开发行人民币普通股 10,000,000 股，每 股面值人民币 1.00 元，溢价发行，每股发行价为人民币 72.65 元，募集资金总额 为人民币 726,500,00 ...